Market Cap $158.9M
!


Corporate Spotlight
Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug development company focused on delivering new therapies to address unmet medical needs.
View the full Corporate Spotlight
PAR - close to a cure for osteoarthritis?
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
PAR | Ann: June 2025 Quarterly Activities Report & Appendix 4C | 20:27 | 9 | 2.4K | |||
|
|||||||
PAR | Sharewise Presentation 22/7/24 | 18:44 | 142 | 48K | |||
|
|||||||
PAR | The Phase III Primer! | 17:46 | 24 | 6.0K | |||
|
|||||||
PAR | Ann: Paradigm Investor Webinar | 13:17 | 11 | 4.2K | |||
|
|||||||
PAR | Ann: Paradigm Secures US$27M to Advance Phase 3 OA Trial | 10:07 | 133 | 46K | |||
|
|||||||
PAR | Phase 3 Trial progress | 28/07/25 | 38 | 16K | |||
|
|||||||
PAR | research reports and media | 28/07/25 | 4.6K | 2.2M | |||
|
|||||||
PAR | Chart | 25/07/25 | 4.9K | 4.1M | |||
|
See All Discussions
Timeline
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
View More |